BR112019015633A2 - Métodos, matrizes e utilizações dos mesmos - Google Patents

Métodos, matrizes e utilizações dos mesmos Download PDF

Info

Publication number
BR112019015633A2
BR112019015633A2 BR112019015633-0A BR112019015633A BR112019015633A2 BR 112019015633 A2 BR112019015633 A2 BR 112019015633A2 BR 112019015633 A BR112019015633 A BR 112019015633A BR 112019015633 A2 BR112019015633 A2 BR 112019015633A2
Authority
BR
Brazil
Prior art keywords
fact
biomarkers
weeks
pancreatic cancer
petition
Prior art date
Application number
BR112019015633-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Borrebaeck Carl
Dexlin Mellby Linda
Nyberg Andreas
Wingren Christer
Original Assignee
Immunovia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovia Ab filed Critical Immunovia Ab
Publication of BR112019015633A2 publication Critical patent/BR112019015633A2/pt

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57438Specifically defined cancers of liver, pancreas or kidney
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BR112019015633-0A 2017-01-31 2018-01-31 Métodos, matrizes e utilizações dos mesmos BR112019015633A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1701572.8A GB201701572D0 (en) 2017-01-31 2017-01-31 Methods, arrays and uses thereof
GB1701572.8 2017-01-31
PCT/EP2018/052423 WO2018141804A1 (en) 2017-01-31 2018-01-31 Methods, arrays and uses thereof

Publications (1)

Publication Number Publication Date
BR112019015633A2 true BR112019015633A2 (pt) 2020-03-17

Family

ID=58462729

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019015633-0A BR112019015633A2 (pt) 2017-01-31 2018-01-31 Métodos, matrizes e utilizações dos mesmos

Country Status (13)

Country Link
US (1) US20190382849A1 (enExample)
EP (1) EP3577464A1 (enExample)
JP (1) JP2020507760A (enExample)
KR (1) KR20190109422A (enExample)
CN (1) CN110325860A (enExample)
AU (1) AU2018214180A1 (enExample)
BR (1) BR112019015633A2 (enExample)
CA (1) CA3051968A1 (enExample)
GB (1) GB201701572D0 (enExample)
IL (1) IL268244A (enExample)
MX (1) MX2019008911A (enExample)
RU (1) RU2019123695A (enExample)
WO (1) WO2018141804A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008117067A2 (en) 2007-03-27 2008-10-02 Carl Arne Krister Borrebaeck Protein signature/markers for the detection of adenocarcinoma
CA3142634A1 (en) * 2019-07-03 2021-01-07 Crystal Bioscience Inc. Anti-b7-h3 antibody and methods of use thereof
KR102289278B1 (ko) * 2019-07-09 2021-08-13 주식회사 베르티스 췌장암 진단용 바이오마커 패널 및 그 용도
JP2023507369A (ja) * 2019-12-20 2023-02-22 メディミューン,エルエルシー グリピカン3を標的とするキメラ抗原受容体を用いて癌を治療する組成物及び方法
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof
AU2022244125A1 (en) * 2021-03-26 2023-10-19 BioNTech SE Combination therapy with an anti-ca19-9 antibody and folfirinox in the treatment of cancer
CN113336851B (zh) * 2021-06-30 2021-12-24 徐州医科大学 新型全人源抗人b7h3抗体、包含所述抗体的组合物及其应用
CN120177800B (zh) * 2025-05-23 2025-10-10 四川大学 血液生物标志物cfp在制备急性胰腺炎诊断试剂的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US8632983B2 (en) * 2005-04-15 2014-01-21 Van Andel Research Institute Biomarkers for pancreatic cancer and diagnostic methods
WO2008117067A2 (en) 2007-03-27 2008-10-02 Carl Arne Krister Borrebaeck Protein signature/markers for the detection of adenocarcinoma
WO2012031374A1 (zh) * 2010-09-09 2012-03-15 北京同为时代生物技术有限公司 用于诊断上皮源性癌症的血液标志物及其单克隆抗体
GB201103726D0 (en) 2011-03-04 2011-04-20 Immunovia Ab Method, array and use thereof
GB201206323D0 (en) * 2012-04-10 2012-05-23 Immunovia Ab Methods and arrays for use in the same
GB201319878D0 (en) * 2013-11-11 2013-12-25 Immunovia Ab Method, Array and use thereof
GB201516801D0 (en) * 2015-09-22 2015-11-04 Immunovia Ab Method, array and use thereof

Also Published As

Publication number Publication date
US20190382849A1 (en) 2019-12-19
JP2020507760A (ja) 2020-03-12
KR20190109422A (ko) 2019-09-25
AU2018214180A1 (en) 2019-08-08
CA3051968A1 (en) 2018-08-09
IL268244A (en) 2019-09-26
GB201701572D0 (en) 2017-03-15
EP3577464A1 (en) 2019-12-11
CN110325860A (zh) 2019-10-11
RU2019123695A (ru) 2021-03-02
MX2019008911A (es) 2019-09-26
WO2018141804A1 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
BR112019015633A2 (pt) Métodos, matrizes e utilizações dos mesmos
Mellby et al. Serum biomarker signature-based liquid biopsy for diagnosis of early-stage pancreatic cancer
US20220206004A1 (en) Method, array and use thereof
JP6161542B2 (ja) 方法、アレイ及びその使用
EP3353552B1 (en) Method and array for diagnosing pancreatic cancer in an individual
US9791446B2 (en) Signatures and determinants for distinguishing between a bacterial and viral infection and methods of use thereof
ES2704888T3 (es) Método, matriz y uso de los mismos para determinar cáncer de páncreas
US11320436B2 (en) Methods, arrays and uses thereof
Chauvin et al. Clinical proteomics in colorectal cancer, a promising tool for improving personalised medicine
GB2551415A (en) Protein biomarker panels for detecting colorectal cancer and advanced adenoma
US20170192004A1 (en) Methods and Arrays for Use in the Same
Ibrahim et al. Differentiating active from stable vitiligo: the role of dermoscopic findings and their relation to CXCL10
Zhou et al. Preoperative Prediction of Sarcopenia in Patients Scheduled for Gastric and Colorectal Cancer Surgery
CN120102887B (zh) 一种检测肺癌的联检产品及其应用
Yu Etiology and early detection of pancreatic cancer
Lin et al. Application of proximity ligation assays to identify potential plasma biomarkers in oral cavity cancer patients: A case control study

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]